Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Nov 17;11(11):CD012437.
doi: 10.1002/14651858.CD012437.

Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA)

Jasvinder A Singh  1 , Alomgir Hossain, Elizabeth Tanjong Ghogomu, Amy S Mudano, Peter Tugwell, George A Wells
Affiliations
Review

Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA)

Jasvinder A Singh et al. Cochrane Database Syst Rev. .

Abstract

Background: We performed a systematic review, a standard meta-analysis and network meta-analysis (NMA), which updates the 2009 Cochrane Overview, 'Biologics for rheumatoid arthritis (RA)'. This review is focused on biologic monotherapy in people with RA in whom treatment with traditional disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) had failed (MTX/other DMARD-experienced).

Objectives: To assess the benefits and harms of biologic monotherapy (includes anti-tumor necrosis factor (TNF) (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab) or non-TNF (abatacept, anakinra, rituximab, tocilizumab)) or tofacitinib monotherapy (oral small molecule) versus comparator (placebo or MTX/other DMARDs) in adults with RA who were MTX/other DMARD-experienced.

Methods: We searched for randomized controlled trials (RCTs) in the Cochrane Central Register of Controlled Trials (CENTRAL; The Cochrane Library 2015, Issue 6, June), MEDLINE (via OVID 1946 to June 2015), and Embase (via OVID 1947 to June 2015). Article selection, data extraction and risk of bias and GRADE assessments were done in duplicate. We calculated direct estimates with 95% confidence intervals (CI) using standard meta-analysis. We used a Bayesian mixed treatment comparisons (MTC) approach for NMA estimates with 95% credible intervals (CrI). We converted odds ratios (OR) to risk ratios (RR) for ease of understanding. We calculated absolute measures as risk difference (RD) and number needed to treat for an additional beneficial outcome (NNTB).

Main results: This update includes 40 new RCTs for a total of 46 RCTs, of which 41 studies with 14,049 participants provided data. The comparator was placebo in 16 RCTs (4,532 patients), MTX or other DMARD in 13 RCTs (5,602 patients), and another biologic in 12 RCTs (3,915 patients). Monotherapy versus placeboBased on moderate-quality direct evidence, biologic monotherapy (without concurrent MTX/other DMARDs) was associated with a clinically meaningful and statistically significant improvement in American College of Rheumatology score (ACR50) and physical function, as measured by the Health Assessment Questionnaire (HAQ) versus placebo. RR was 4.68 for ACR50 (95% CI, 2.93 to 7.48); absolute benefit RD 23% (95% CI, 18% to 29%); and NNTB = 5 (95% CI, 3 to 8). The mean difference (MD) was -0.32 for HAQ (95% CI, -0.42 to -0.23; a negative sign represents greater HAQ improvement); absolute benefit of -10.7% (95% CI, -14% to -7.7%); and NNTB = 4 (95% CI, 3 to 5). Direct and NMA estimates for TNF biologic, non-TNF biologic or tofacitinib monotherapy showed similar results for ACR50 , downgraded to moderate-quality evidence. Direct and NMA estimates for TNF biologic, anakinra or tofacitinib monotherapy showed a similar results for HAQ versus placebo with mostly moderate quality evidence.Based on moderate-quality direct evidence, biologic monotherapy was associated with a clinically meaningful and statistically significant greater proportion of disease remission versus placebo with RR 1.12 (95% CI 1.03 to 1.22); absolute benefit 10% (95% CI, 3% to 17%; NNTB = 10 (95% CI, 8 to 21)).Based on low-quality direct evidence, results for biologic monotherapy for withdrawals due to adverse events and serious adverse events were inconclusive, with wide confidence intervals encompassing the null effect and evidence of an important increase. The direct estimate for TNF monotherapy for withdrawals due to adverse events showed a clinically meaningful and statistically significant result with RR 2.02 (95% CI, 1.08 to 3.78), absolute benefit RD 3% (95% CI,1% to 4%), based on moderate-quality evidence. The NMA estimates for TNF biologic, non-TNF biologic, anakinra, or tofacitinib monotherapy for withdrawals due to adverse events and for serious adverse events were all inconclusive and downgraded to low-quality evidence. Monotherapy versus active comparator (MTX/other DMARDs)Based on direct evidence of moderate quality, biologic monotherapy (without concurrent MTX/other DMARDs) was associated with a clinically meaningful and statistically significant improvement in ACR50 and HAQ scores versus MTX/other DMARDs with a RR of 1.54 (95% CI, 1.14 to 2.08); absolute benefit 13% (95% CI, 2% to 23%), NNTB = 7 (95% CI, 4 to 26) and a mean difference in HAQ of -0.27 (95% CI, -0.40 to -0.14); absolute benefit of -9% (95% CI, -13.3% to -4.7%), NNTB = 2 (95% CI, 2 to 4). Direct and NMA estimates for TNF monotherapy and NMA estimate for non-TNF biologic monotherapy for ACR50 showed similar results, based on moderate-quality evidence. Direct and NMA estimates for non-TNF biologic monotherapy, but not TNF monotherapy, showed similar HAQ improvements , based on mostly moderate-quality evidence.There were no statistically significant or clinically meaningful differences for direct estimates of biologic monotherapy versus active comparator for RA disease remission. NMA estimates showed a statistically significant and clinically meaningful difference versus active comparator for TNF monotherapy (absolute improvement 7% (95% CI, 2% to 14%)) and non-TNF monotherapy (absolute improvement 19% (95% CrI, 7% to 36%)), both downgraded to moderate quality.Based on moderate-quality direct evidence from a single study, radiographic progression (scale 0 to 448) was statistically significantly reduced in those on biologic monotherapy versus active comparator, MD -4.34 (95% CI, -7.56 to -1.12), though the absolute reduction was small, -0.97% (95% CI, -1.69% to -0.25%). We are not sure of the clinical relevance of this reduction.Direct and NMA evidence (downgraded to low quality), showed inconclusive results for withdrawals due to adverse events, serious adverse events and cancer, with wide confidence intervals encompassing the null effect and evidence of an important increase.

Authors' conclusions: Based mostly on RCTs of six to 12-month duration in people with RA who had previously experienced and failed treatment with MTX/other DMARDs, biologic monotherapy improved ACR50, function and RA remission rates compared to placebo or MTX/other DMARDs.Radiographic progression was reduced versus active comparator, although the clinical significance was unclear.Results were inconclusive for whether biologic monotherapy was associated with an increased risk of withdrawals due to adverse events, serious adverse events or cancer, versus placebo (no data on cancer) or MTX/other DMARDs.

PubMed Disclaimer

Conflict of interest statement

JS ‐ JS has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron, Iroko, Merz, Bioiberica, Crealta and Allergan pharmaceuticals, WebMD, Medscape, the American College of Rheumatology and UBM, LLC. JS serves as the principal investigator for an investigator‐initiated study funded by Horizon pharmaceuticals through a grant to DINORA, Inc., a 501c3 entity. JS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms‐length funding from 36 companies; a member of the American College of Rheumatology's Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. AH ‐ none ETG ‐ none RC ‐ research grant and consultant fee (paid to his institution) from Abbott/Abbvie, MSD, Norpharma/Mundipharma, Roche AM ‐ none PT ‐ grants/honoraria from Bristol Myers, Chiltern International, and UCB GW ‐ research grant and consultant fee from Bristol‐Myers Squibb

Figures

1
1
PRISMA study flow diagram
2
2
Network diagram for cancer: biologic monotherapy
3
3
ACR50: biologic monotherapy vs placebo
4
4
ACR50: biologic monotherapy vs placebo by drug group
5
5
ACR50: biologic monotherapy vs MTX/DMARD
6
6
ACR50: biologic monotherapy vs MTX/DMARD by drug group
7
7
HAQ: biologic monotherapy vs placebo
8
8
HAQ: biologic monotherapy vs placebo by drug group
9
9
HAQ: biologic monotherapy vs MTX/DMARD
10
10
HAQ: biologic monotherapy vs MTX/DMARD by drug group
11
11
Remission: biologic monotherapy vs placebo
12
12
Remission: biologic monotherapy vs MTX/DMARD
13
13
Remission: biologic monotherapy vs MTX/DMARD by drug group
14
14
Radiographic progression: biologic monotherapy vs MTX/DMARD
15
15
Withdrawals due to Adverse Events: biologic monotherapy vs placebo
16
16
Withdrawals due to Adverse Events: biologic monotherapy vs placebo by drug group
17
17
Withdrawals due to Adverse Events: biologic monotherapy vs MTX/DMARD
18
18
Withdrawals due to Adverse Events: biologic monotherapy vs MTX/DMARD by drug group
19
19
Serious Adverse Events: biologic monotherapy vs placebo
20
20
Serious Adverse Events: biologic monotherapy vs placebo by drug group
21
21
Serious Adverse Events: biologic monotherapy vs MTX/DMARD
22
22
Serious Adverse Events: biologic monotherapy vs MTX/DMARD by drug group
23
23
Cancer: biologic monotherapy vs MTX/DMARD
24
24
Cancer: biologic monotherapy vs MTX/DMARD by drug group
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to included reviews

Boyle 2015
    1. Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1‐STAT signalling in rheumatoid arthritis. Ann Rheum Dis 2015;74:1311‐6. - PMC - PubMed
Bresnihan 1998
    1. Bresnihan B, Alvaro‐Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin‐1 receptor antagonist. Arthritis Rheum 1998;41:2196‐204. - PubMed
Burmester 2014
    1. Burmester GR, Rubbert‐Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, et al. A randomised, double‐blind, parallel‐group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease‐modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 2014;73:69‐74. - PMC - PubMed
Combe 2009
    1. Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Efficacy, safety and patient‐reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double‐blind randomised 2‐year study. Ann Rheum Dis 2009;68:1146‐52. - PMC - PubMed
Coombs 2010
    1. Coombs JH, Bloom BJ, Breedveld FC, Fletcher MP, Gruben D, Kremer JM, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP‐690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double‐blind, placebo‐controlled trial. Ann Rheum Dis 2010;69:413‐6. - PubMed
Dougados 2013
    1. Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24‐week symptomatic and structural results of a 2‐year randomised controlled strategy trial in rheumatoid arthritis (ACT‐RAY). Ann Rheum Dis 2013;72:43‐50. - PMC - PubMed
Doyle 2013
    1. Doyle MK, Rahman MU, Frederick B, Birbara CA, Vries D, Toedter G, et al. Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open‐label trial. Rheumatology (Oxford) 2013;52:1214‐9. - PubMed
Edwards 2004
    1. Edwards JC, Szczepanski L, Szechinski J, Filipowicz‐Sosnowska A, Emery P, Close DR, et al. Efficacy of B‐cell‐targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572‐81. - PubMed
Fleischmann 2012a
    1. Fleischmann R, Kremer J, Cush J, Schulze‐Koops H, Connell CA, Bradley JD, et al. Placebo‐controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495‐507. - PubMed
Fleischmann 2012b
    1. Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, et al. Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs. Arthritis Rheum 2012;64:617‐29. - PubMed
Gabay 2013b
    1. Gabay C, Emery P, Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double‐blind, controlled phase 4 trial. Lancet 2013;381:1541‐50. - PubMed
Genovese 2002
    1. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two‐year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443‐50. - PubMed
Hobbs 2015
    1. Hobbs K, Deodhar A, Wang B, Bitman B, Nussbaum J, Chung J, et al. Randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy. Springerplus 2015;4:113. - PMC - PubMed
Huizinga 2015
    1. Huizinga TW, Conaghan PG, Martin‐Mola E, Schett G, Amital H, Xavier RM, et al. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT‐RAY study. Ann Rheum Dis 2015;74:35‐43. - PMC - PubMed
Jobanputra 2012
    1. Jobanputra P, Maggs F, Deeming A, Carruthers D, Rankin E, Jordan AC, et al. A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non‐inferiority study of first TNF inhibitor use: outcomes over 2 years. BMJ Open 2012;2(6):e001395. - PMC - PubMed
Johnsen 2006
    1. Johnsen AK, Schiff MH, Mease PJ, Moreland LW, Maier AL, Coblyn JS, et al. Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. J Rheumatol 2006;33:659‐64. - PubMed
Jones 2010
    1. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez‐Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88‐96. - PMC - PubMed
Kameda 2010
    1. Kameda H, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, et al. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. Mod Rheumatol 2010;20:531‐8. - PubMed
Keystone 2009
    1. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO‐FORWARD Study. Ann Rheum Dis 2009;68:789‐96. - PMC - PubMed
Kremer 2009
    1. Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo. Arthritis Rheum 2009;60:1895‐905. - PubMed
Kremer 2010
    1. Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, et al. Golimumab, a new human anti‐tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: forty‐eight‐week efficacy and safety results of a phase III randomized, double‐blind, placebo‐controlled study. Arthritis Rheum 2010;62:917‐28. - PubMed
Kremer 2013
    1. Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin‐Mola E, et al. Tofacitinib in combination with nonbiologic disease‐modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 2013;159:253‐61. - PubMed
MacIsaac 2014
    1. MacIsaac KD, Baumgartner R, Kang J, Loboda A, Peterfy C, DiCarlo J, et al. Pre‐treatment whole blood gene expression is associated with 14‐week response assessed by dynamic contrast enhanced magnetic resonance imaging in infliximab‐treated rheumatoid arthritis patients. PloS One 2014;9(12):e113937. - PMC - PubMed
Maini 2006
    1. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double‐blind randomized controlled clinical trial of the interleukin‐6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817‐29. - PubMed
Mathias 2000
    1. Mathias SD, Colwell HH, Miller DP, Moreland LW, Buatti M, Wanke L. Health‐related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin Ther 2000;22:128‐39. - PubMed
Miyasaka 2008
    1. Miyasaka N, Investigators CS. Clinical investigation in highly disease‐affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol 2008;18:252‐62. - PMC - PubMed
Moreland 1999
    1. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478‐86. - PubMed
Moreland 2012
    1. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, Clair EW, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis and Rheumatism 2012;64(9):2824‐35. - PMC - PubMed
Nishimoto 2004
    1. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti‐interleukin‐6 receptor antibody: a multicenter, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism 2004;50(6):1761‐9. - PubMed
Nishimoto 2007
    1. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL‐6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X‐ray reader‐blinded randomised controlled trial of tocilizumab. Annals of the Rheumatic Diseases 2007;66(9):1162‐7. - PMC - PubMed
Ohta 2014
    1. Ohta S, Tsuru T, Terao K, Mogi S, Suzaki M, Shono E, et al. Mechanism‐based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). Journal of Clinical Pharmacology 2014 Jan;54(1):109‐19. - PMC - PubMed
Pavelka 2009
    1. Pavelka K, Jarosová K, Suchý D, Senolt L, Chroust K, Dusek L, et al. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. Annals of the Rheumatic Diseases 2009;68(8):1285‐9. - PubMed
Pope 2014
    1. Pope JE, Haraoui B, Thorne JC, Vieira A, Poulin‐Costello M, Keystone EC. The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis. Ann Rheum Dis 2014;73:2144‐51. - PMC - PubMed
Strand 2006
    1. Strand V, Balbir‐Gurman A, Pavelka K, Emery P, Li N, Yin M, et al. Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years. Rheumatology (Oxford) 2006;45:1505‐13. - PubMed
Tada 2012
    1. Tada M, Koike T, Okano T, Sugioka Y, Wakitani S, Fukushima K, et al. Comparison of joint destruction between standard‐ and low‐dose etanercept in rheumatoid arthritis from the Prevention of Cartilage Destruction by Etanercept (PRECEPT) study. Rheumatology (Oxford) 2012;51:2164‐9. - PubMed
Takeuchi 2013a
    1. Takeuchi T, Matsubara T, Nitobe T, Suematsu E, Ohta S, Honjo S, et al. Phase II dose‐response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. Mod Rheumatol 2013;23:226‐35. - PubMed
Takeuchi 2013b
    1. Takeuchi T, Miyasaka N, Zang C, Alvarez D, Fletcher T, Wajdula J, et al. A phase 3 randomized, double‐blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis. Mod Rheumatol 2013;23:623‐33. - PubMed
Takeuchi 2013c
    1. Takeuchi T, Harigai M, Tanaka Y, Yamanaka H, Ishiguro N, Yamamoto K, et al. Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease‐modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double‐blind, placebo‐controlled GO‐MONO study through 24 weeks. Ann Rheum Dis 2013;72:1488‐95. - PMC - PubMed
Van de Putte 2003
    1. Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, Riel PL, et al. Efficacy and safety of the fully human anti‐tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis 2003;62:1168‐77. - PMC - PubMed
Van de Putte 2004
    1. Putte LB, Atkins C, Malaise M, Sany J, Russell AS, Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508‐16. - PMC - PubMed
Van der Heidje 2006
    1. Heijde D, Klareskog L, Rodriguez‐Valverde V, Codreanu C, Bolosiu H, Melo‐Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two‐year clinical and radiographic results from the TEMPO study, a double‐blind, randomized trial. Arthritis and Rheumatism 2006;54:1063‐74. - PubMed
Van der Heijde 2007
    1. Heijde D, Klareskog L, Landewe R, Bruyn GA, Cantagrel A, Durez P, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:3928‐39. - PubMed
Van Riel 2006
    1. Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 2006;65:1478‐83. - PMC - PubMed
Van Riel 2008
    1. Riel PL, Freundlich B, MacPeek D, Pedersen R, Foehl JR, Singh A. Patient‐reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. Annals of the Rheumatic Diseases 2008;67(8):1104‐10. - PubMed
Yamamoto 2014a
    1. Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J‐RAPID randomized, placebo‐controlled trial. Mod Rheumatol 2014;24:715‐24. - PubMed
Østergaard 2015
    1. Østergaard M, Jacobsson LT, Schaufelberger C, Hansen MS, Bijlsma JW, Dudek A, et al. MRI assessment of early response to certolizumabpegol in rheumatoid arthritis: a randomised,double‐blind, placebo‐controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16. Annals of the Rheumatic Diseases 2015;74:1156–63. [DOI] - PMC - PubMed

References to excluded reviews

Abe 2006
    1. Abe T, Takeuchi T, Miyasaka N. Hashimoto H, Kondo H, Ichikawa Y, et al. A multicenter, double‐blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. The Journal of Rheumatology 2006;33:37‐44. - PubMed
Axelsen 2015
    1. Axelsen MB, Eshed I, Hørslev‐Petersen K, Stengaard‐Pedersen K, Hetland ML, Møller J, et al. A treat‐to‐target strategy with methotrexate and intra‐articular triamcinolone with or without adalimumab effectively reduces MRI synovitis,osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial. Annals of the Rheumatic Diseases 2015;74:867–75. - PubMed
Bae 2013
    1. Bae SC, Gun SC, Mok CC, Khandker R, Nab HW, Koenig AS, et al. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis. BMC Musculoskeletal Disorders 2013;14:13. - PMC - PubMed
Bathon 2000
    1. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. New England Journal of Medicine 2000;343(22):1586‐93. - PubMed
Bejarano 2008
    1. Bejarano V, Quinn MA, Conaghan PG, Reece R, Keenan AM, Walker D, et al. Effect of the early use of the anti–tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis and Rheumatism 2008;59(10):1467‐74. - PubMed
Bingham 2015
    1. Bingham CO 3rd, Rizzo W, Kivitz A, Hassanali A, Upmanyu R, Klearman M. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Annals of the Rheumatic Diseases 2015;74(5):818‐22. - PMC - PubMed
Bonafede 2015
    1. Bonafede M, Johnson BH, Tang DH, Shah N, Harrison DJ, Collier DH. Etanercept‐methotrexate combination therapy initiators have greater adherence and persistence than triple therapy initiators with rheumatoid arthritis. Arthritis Care and Research (Hoboken) 2015;67(12):1656‐63. - PMC - PubMed
Breedveld 2006
    1. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis and Rheumatism 2006;54:26‐37. - PubMed
Burmester 2013
    1. Burmester GR, Blanco R, Charles‐Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP‐690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013;381(9865):451‐60. - PubMed
Burmester 2015
    1. Burmester GR, Kivitz AJ, Kupper H, Arulmani U, Florentinus S, Goss SL, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Annals of the Rheumatic Diseases 2015;74(6):1037‐44. - PMC - PubMed
Chen 2009
    1. Chen DY, Chou SJ, Hsieh TY, Chen YH, Chen HH, Hsieh CW, et al. Randomized, double‐blind, placebo‐controlled, comparative study of human anti‐TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. Journal of the Formosan Medical Association 2009;108:310‐9. - PubMed
Cheng 2014
    1. Cheng T, Wang M, Chen Z, Eisenberg RA, Zhang Y, Zou Y, et al. Tartrate‐resistant acid phosphatase 5b is a potential biomarker for rheumatoid arthritis: a pilot study in Han Chinese. Chinese Medical Journal 2014;127(16):2894‐9. - PubMed
Choy 2012
    1. Choy E, McKenna F, Vencovsky J, Valente R, Goel N, Vanlunen B, et al. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. Rheumatology 2012;51:1226‐34. - PubMed
Cohen 2002
    1. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin‐1 receptor antagonist, in combination with methotrexate: results of a twenty‐four‐week, multicenter, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatology 2002;46:614‐24. - PubMed
Cohen 2003
    1. Cohen M, Wolfe R, Mai T, Lewis D. A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. Journal of Rheumatology 2003;30(3):523‐8. - PubMed
Cohen 2004
    1. Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Annals of the Rheumatic Diseases 2004;63:1062‐8. - PMC - PubMed
Cohen 2006
    1. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti‐tumor necrosis factor therapy: results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks. Arthritis and Rheumatism 2006;54(9):2793‐806. - PubMed
Combe 2006
    1. Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double‐blind comparison. Annals of the Rheumatic Diseases 2006;65:1357‐62. - PMC - PubMed
Conaghan 2013
    1. Conaghan PG, Durez P, Alten RE, Burmester GR, Tak PP, Klareskog L, et al. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Annals of the Rheumatic Diseases 2013;72:1287‐94. - PMC - PubMed
Conaghan 2014
    1. Conaghan PG, Peterfy C, Olech E, Kaine J, Ridley D, DiCarlo J, et al. The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT‐RAY MRI substudy. Annals of the Rheumatic Diseases 2014;73(5):810‐6. - PMC - PubMed
Detert 2013
    1. Detert J, Bastian H, Listing J, Weiß A, Wassenberg S, Liebhaber A, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD‐naïve patients with early rheumatoid arthritis: HIT HARD, an investigator‐initiated study. Annals of the Rheumatic Diseases 2013;72:844–50. - PubMed
Dougados 2014
    1. Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab‐based treatment strategies in rheumatoid arthritis: the ACT‐RAY study. Annals of the Rheumatic Diseases 2014;73(5):803‐9. - PMC - PubMed
Durez 2004
    1. Durez P, Nzeusseu Toukap A, Lauwerys BR, Manicourt DH, Verschueren P, Westhovens R, et al. A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. Arthritis and Rheumatism 2004;63:1069‐74. - PMC - PubMed
Durez 2007
    1. Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R, et al. Treatment of early rheumatoid arthritis. A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis and Rheumatism 2007;56(12):3919–27. - PubMed
Emery 2006
    1. Emery P, Fleischmann R, Filipowicz‐Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial. Arthritis and Rheumatology 2006;54:1390‐400. - PubMed
Emery 2008
    1. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double‐blind, parallel treatment trial. Lancet 2008;372:375‐82. - PubMed
Emery 2010
    1. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo‐controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Annals of the Rheumatic Diseases 2010;69:1629‐35. - PMC - PubMed
Emery 2014a
    1. Emery P, Hammoudeh M, FitzGerald O, Combe B, Martin‐Mola E, Buch MH, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. New England Journal of Medicine 2014;371(19):1781‐92. - PubMed
Emery 2014b
    1. Emery P, Fleischmann RM, Hsia EC, Xu S, Zhou Y, Baker D. Efficacy of golimumab plus methotrexate in methotrexate‐naïve patients with severe active rheumatoid arthritis. Clinical Rheumatology 2014;33(9):1239‐46. - PubMed
Eriksson 2015
    1. Eriksson JK, Karlsson JA, Bratt J, Petersson IF, Vollenhoven RF, Ernestam S, et al. Cost‐effectiveness of infliximab versus conventional combination treatment in methotrexate‐refractory early rheumatoid arthritis: 2‐year results of the register‐enriched randomised controlled SWEFOT trial. Annals of the Rheumatic Disease 2015;74(6):1094‐101. - PMC - PubMed
Fleischmann 2003
    1. Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, et al. Anakinra, a recombinant human interleukin‐1 receptor antagonist (r‐metHuIL‐1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo‐controlled trial. Arthritis and Rheumatology 2003;48:927‐34. - PubMed
Fleischmann 2009
    1. Fleischmann R, Vencovsky J, Vollenhoven RF, Borenstein D, Box J, Coteur G, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease‐modifying antirheumatic therapy: the FAST4WARD study. Annals of the Rheumatic Diseases 2009;68:805‐11. - PMC - PubMed
Fleischmann 2013
    1. Fleischmann R, Weinblatt ME, Schiff M, Khanna D, Maldonado MA, Nadkarni A, et al. 2‐year results from the Ample (Abatacept versus adalimumab comparison in biologic‐naïve RA patients with background Methotrexate) trial: changes in patient‐reported outcomes in response to subcutaneous abatacept or adalimumab in rheumatoid arthritis. Arthritis and Rheumatism 2013;65(Suppl 10):S577.
Fleischmann 2014
    1. Fleischmann R, Weinblatt ME, Schiff M, Khanna D, Maldonado MA, Nadkarni A. 2‐year results from the Ample (abatacept versus adalimumab comparison in biologic‐naïve RA patients with background methotrexate) trial: changes in patient‐reported outcomes in response to subcutaneous abatacept or adalimumab In rheumatoid arthritis.. Arthritis and Rheumatism 2014;65(Suppl 10):424.
Furst 2003
    1. Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor‐alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). Journal of Rheumatology 2003;30:2563‐71. - PubMed
Furst 2007
    1. Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, et al. Open‐label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Annals of the Rheumatic Diseases 2007;66(7):893‐9. - PMC - PubMed
Furst 2015
    1. Furst DE, Shaikh SA, Greenwald M, Bennett B, Davies O, Luijtens K, et al. Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis. Arthritis Care and Research (Hoboken) 2015;67(2):151‐60. [DOI] - PMC - PubMed
Gashi 2014
    1. Gashi AA, Rexhepi S, Berisha I, Kryeziu A, Ismaili J, Krasniqi G. Treatment of rheumatoid arthritis with biologic DMARDS (rituximab and etanercept). Medical Archives 2014;68(1):51‐3. - PMC - PubMed
Genovese 2004
    1. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis and Rheumatology 2004;50:1412‐9. - PubMed
Genovese 2005
    1. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. New England Journal of Medicine 2005;353(11):1114‐23. - PubMed
Genovese 2008
    1. Genovese MC, McKay JD, Nasonov EL, Mysler EF, Silva NA, Alecock E, et al. Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: the tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy study. Arthritis and Rheumatology 2008;58:2968‐80. - PubMed
Genovese 2011
    1. Genovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb non‐inferiority study in patients with an inadequate response to methotrexate. Arthritis and Rheumatology 2011;63:2854‐64. - PMC - PubMed
Genovese 2014
    1. Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, Dasgupta B, et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Annals of the Rheumatic Diseases 2014;73(9):1607‐15. - PMC - PubMed
Gherge 2014
    1. Gherge AM, Ramiro S, Landewé R, Mihai C, Heidje D. THU0229 association of radiographic damage with physical function in patients with rheumatoid arthritis – results from the RAPID1 Trial. Annals of the Rheumatic Diseases 2014;73(Suppl 2):261.
Goekoop‐Ruiterman 2007
    1. Goekoop‐Ruiterman YP, Vries‐Bouwstra JK, Allaart CF, Zeben D, Kerstens PJ, Hazes JM, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Annals of Internal Medicine 2007;146:406‐15. - PubMed
Haraoui 2014
    1. Haraoui B, Thorne JC, Keystone EC, Poulin‐Costello M, Trottier E, Vieira A, et al. Clinical and radiographic outcomes with etanercept and etanercept and methotrexate in patients with rheumatoid arthritis: two‐year results from the Canadian Methotrexate And Etanercept Outcome Study (CAMEO). Arthritis and Rheumatism 2014;65(Suppl 10):1464.
Heimans 2014
    1. Heimans L, Wevers‐de Boer KV, Visser K, Goekoop RJ, Oosterhout M, Harbers JB, et al. A two‐step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Annals of the Rheumatic Diseases 2014;73(7):1356‐61. - PubMed
Hørslev‐Petersen 2014
    1. Hørslev‐Petersen K, Hetland ML, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, et al. Adalimumab added to a treat‐to‐target strategy with methotrexate and intra‐articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator‐initiated, randomised, double‐blind, parallel‐group, placebo‐controlled trial. Annals of the Rheumatic Diseases 2014;73(4):654‐61. - PubMed
Iannone 2014
    1. Iannone F, Montagna G, Bagnato G, Gremese E, Giardina A, Lapadula G. Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial. Journal of Rheumatology 2014;41(2):286‐92. - PubMed
Kaine 2011
    1. Kaine J, Gladstein G, Strusberg I, Robles M, Louw I, Gujrathi S, et al. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study). Annals of the Rheumatic Diseases 2012;71:38‐44. - PMC - PubMed
Kameda 2011
    1. Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, et al. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52‐week results from the JESMR study. Journal of Rheumatology 2011;38(8):1585‐92. - PubMed
Kavanaugh 2013
    1. Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26‐week results from the randomised, controlled OPTIMA study. Annals of the Rheumatic Diseases 2013;72(1):64‐71. - PMC - PubMed
Kavanaugh 2014
    1. Kavanaugh A, Mease PJ, Strand V, Purcaru O, Curtis JR. Effect of certolizumab pegol on workplace and household productivity in US patients with rheumatoid arthritis with or without prior anti‐tumor necrosis factor exposure: results from the predict study. Annals of the Rheumatic Diseases 2014;73(Suppl 2):927‐8.
Kay 2008
    1. Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double‐blind, placebo‐controlled, dose‐ranging study. Arthritis and Rheumatism 2008;58(4):964‐75. - PubMed
Kennedy 2014
    1. Kennedy WP, Simon JA, Offutt C, Horn P, Herman A, Townsend MJ, et al. Efficacy and safety of pateclizumab (anti‐lymphotoxin‐alpha) compared to adalimumab in rheumatoid arthritis: a head‐to‐head phase 2 randomized controlled study (The ALTARA Study). Arthritis Research and Therapy 2014;16(5):467. - PMC - PubMed
Keystone 2004a
    1. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti‐tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo‐controlled, 52‐week trial. Arthritis Rheum 2004;50(5):1400‐11. - PubMed
Keystone 2004b
    1. Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, et al. Once‐weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatology 2004;50:353‐63. - PubMed
Keystone 2008
    1. Keystone E, Burmester GR, Furie R, Loveless JE, Emery P, Kremer J, et al. Improvement in patient‐reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti–tumor necrosis factor therapy. Arthritis and Rheumatism 2008;59(6):785–93. - PubMed
Keystone 2014
    1. Keystone EC, Anisfeld A, Ogale S, Devenport JN, Curtis JR. Continued benefit of tocilizumab plus disease‐modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatment. Journal of Rheumatology 2014;41(2):216‐26. - PubMed
Kim 2007
    1. Kim HY, Lee SK, Song YW, Yoo DH, Koh EM, Yoo B, et al. A randomized, double‐blind, placebo‐controlled, phase III study of the human anti‐tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. APLAR Journal of Rheumatology 2007;10:9‐16.
Kim 2012
    1. Kim HY, Hsu PN, Barba M, Sulaiman W, Robertson D, Vlahos B, et al. Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial. International Journal of Rheumatic Diseases 2012;15(2):188‐96. - PubMed
Kim 2013
    1. Kim J, Ryu H, Yoo DH, Park SH, Song GG, Park W, et al. A clinical trial and extension study of infliximab in Korean patients with active rheumatoid arthritis despite methotrexate treatment. Journal of Korean Medical Science 2013;28:1716‐22. - PMC - PubMed
Kivitz 2014
    1. Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro‐Sarabia F, Radominski SC, et al. Subcutaneous tocilizumab versus placebo in combination with disease‐modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care and Research 2014;66:1653‐61. - PMC - PubMed
Koroleva 2014a
    1. Koroleva MV, Raskina TA. Effect of rituximab therapy on life quality with rheumatoid arthritis patients. Osteoporosis International 2014;25:S365‐6.
Koroleva 2014b
    1. Koroleva MV, Raskina TA. The effect of rituximab therapy on bone mineral density with rheumatoid arthritis patients. Osteoporosis International 2014;25:S374.
Kremer 2003
    1. Kremer JM, Westhovens R, Leon M, Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T‐cell activation with fusion protein CTLA4Ig. New England Journal of Medicine 2003;349:1907‐15. - PubMed
Kremer 2005
    1. Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve‐month results of a phase iib, double‐blind, randomized, placebo‐controlled trial. Arthritis and Rheumatology 2005;52:2263‐71. - PubMed
Kremer 2006
    1. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud‐Mendoza C, et al. Effects of abatacept in patients with methotrexate‐resistant active rheumatoid arthritis: a randomized trial. Annals of Internal Medicine 2006;144:865‐76. - PubMed
Kremer 2011
    1. Kremer JM, Blanco R, Brzosko M, Burgos‐Vargas R, Halland AM, Vernon E, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double‐blind treatment phase of a randomized placebo‐controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis and Rheumatology 2011;63(3):609‐21. - PubMed
Kremer 2012
    1. Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez‐Reino J, et al. A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis and Rheumatology 2012;64:970‐81. - PubMed
Kremer 2015
    1. Kremer JM, Kivitz AJ, Simon‐Campos JA, Nasonov EL, Tony HP, Lee SK, et al. Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial. Arthritis Research & Therapy 2015;17(95):1‐11. - PMC - PubMed
Lan 2004
    1. Lan JL, Chou SJ, Chen DY, Chen YH, Hsieh TY, Young M. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12‐week, double‐blind, randomized, placebo‐controlled study. Journal of the Formosan Medical Association 2004;103:618‐23. - PubMed
Landewé 2015
    1. Landewé R, Smolen JS, Florentinus S, Chen S, Guérette B, Heijde D. Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis. Arthritis Research and Therapy 2015;17:133. - PMC - PubMed
Lipsky 2000
    1. Lipsky PE, Heijde DM, Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti‐tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000;343(22):1594‐602. - PubMed
Lisbona 2008
    1. Lisbona MP, Maymo J, Perich J, Almirall M, Pérez‐García C, Carbonell J. Etanercept reduces synovitis as measured by magnetic resonance imaging in patients with active rheumatoid arthritis after only 6 weeks. Journal of Rheumatology 2008;35(3):394‐7. - PubMed
Lisbona 2010
    1. Lisbona MP, Maymo J, Perich J, Almirall M, Carbonell J. Rapid reduction in tenosynovitis of the wrist and fingers evaluated by MRI in patients with rheumatoid arthritis after treatment with etanercept. Annals of the Rheumatic Diseases 2010;69:1117‐22. - PubMed
Machado 2014
    1. Machado DA, Guzman RM, Xavier RM, Simon JA, Mele L, Pedersen R, et al. Open‐label observation of addition of etanercept versus a conventional disease‐modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region. Journal of Clinical Rheumatology 2014;20:25‐33. - PubMed
Maini 1999
    1. Maini R, Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti‐tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354(9194):1932‐9. - PubMed
Manders 2015
    1. Manders SH, Kievit W, Adang E, Brus HL, Moens HJ, Hartkamp A, et al. Cost‐effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi‐centre randomised trial. Arthritis Research and Therapy 2015;17(1):134. - PMC - PubMed
Mathias 2000a
    1. Mathias SD, Colwell HH, Miller DP, Moreland LW, Buatti M, Wanke L. Health‐related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clinical Therapeutics 2000;22(1):128‐39. - PubMed
McInnes 2015
    1. McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE, Beaulieu AD, et al. Effect of interleukin‐6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo‐controlled study. Annals of the Rheumatic Diseases 2015;74(4):694‐702. - PMC - PubMed
Moreland 2002
    1. Moreland LW, Alten R, Bosch F, Appelboom T, Leon M, Emery P, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose‐finding, double‐blind, placebo‐controlled clinical trial evaluating CTLA‐4Ig and LEA29Y eighty‐five days after the first infusion. Arthritis and Rheumatism 2002;46(6):1470‐9. - PubMed
Nam 2014a
    1. Nam JL, Villeneuve E, Hensor EM, Conaghan PG, Keen HI, Buch MH, et al. Remission induction comparing infliximab and high‐dose intravenous steroid, followed by treat‐to‐target: a double‐blind, randomised, controlled trial in new‐onset, treatment‐naive, rheumatoid arthritis (the IDEA study). Annals of the Rheumatic Diseases 2014;73(1):75‐85. - PubMed
Nam 2014b
    1. Nam JL, Villeneuve E, Hensor EM, Wakefield RJ, Conaghan PG, Green MJ, et al. A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial. Annals of the Rheumatic Diseases 2014;73(6):1027‐36. - PubMed
Navarro 2014
    1. Navarro Coy NC, Brown S, Bosworth A, Davies CT, Emery P, Everett CC, et al. The ‘Switch’ study protocol: a randomised controlled trial of switching to an alternative tumour‐necrosis factor (TNF)‐inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF‐inhibitor drug. BMC Musculoskeletal Disorders 2014;15:452. - PMC - PubMed
Nishimoto 2009
    1. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL‐6 receptor inhibition therapy. Modern Rheumatology 2009;19:12‐9. - PMC - PubMed
O'Dell 2013
    1. O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al. Therapies for active rheumatoid arthritis after methotrexate failure. New England Journal of Medicine 2013;369:307‐18. - PubMed
Oakley 2014
    1. Oakley S, Esmaili N, Major G, Mathers D, Ratnarajah S, Kallen J, et al. A randomised controlled trial evaluating the effect of humira upon endothelial function in ACPA positive rheumatoid arthritis: an interim analysis. Arthritis and Rheumatology 2014;66:S211.
Pavelka 2013
    1. Pavelka K, Szekanecz Z, Damjanov N, Majdan M, Nasonov E, Mazurov V, et al. Induction of response with etanercept‐methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study. Clinical Rheumatology 2013;32(9):1275‐81. - PubMed
Quinn 2005
    1. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor‐prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve‐month randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism 2005;52(1):27‐35. - PubMed
Rantalaiho 2014
    1. Rantalaiho V, Kautiainen H, Korpela M, Hannonen P, Kaipiainen‐Seppanen O, Mottonen T, et al. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long‐term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5‐year follow‐up results of a randomised clinical trial, the NEO‐RACo trial. Annals of the Rheumatic Diseases 2014;73(11):1954‐61. - PubMed
Rau 2004
    1. Rau R, Simianer S, Riel PL, Putte LB, Krüger K, Schattenkirchner M, et al. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. Scandinavian Journal of Rheumatology 2004;33(3):145‐53. - PubMed
Rigby 2011
    1. Rigby W, Ferraccioli G, Greenwald M, Zazueta‐Montiel B, Fleischmann R, Wassenberg S, et al. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care and Research (Hoboken) 2011;63(5):711‐20. - PubMed
Rubbert‐Roth 2010
    1. Rubbert‐Roth A, Tak PP, Zerbini C, Tremblay JL, Carreño L, Armstrong G, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology (Oxford) 2010;49(9):1683‐93. - PMC - PubMed
Schiff 2004
    1. Schiff MH, DiVittorio G, Tesser J, Fleischmann R, Schechtman J, Hartman S, et al. The safety of anakinra in high‐risk patients with active rheumatoid arthritis: six‐month observations of patients with comorbid conditions. Arthritis and Rheumatism 2004;50(6):1752‐60. - PubMed
Smolen 2008
    1. Smolen JS, Beaulieu A, Rubbert‐Roth A, Ramos‐Remus C, Rovensky J, Alecock E, et al. Effect of interleukin‐6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double‐blind, placebo‐controlled, randomised trial. Lancet 2008;371:987‐97. - PubMed
Smolen 2009
    1. Smolen J, Landewe RB, Mease P, Brzezicki J, Mason D, Luijtens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Annals of the Rheumatic Diseases 2009;68:797‐804. - PMC - PubMed
Smolen 2013a
    1. Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque‐Palazuelos F, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918‐29. - PubMed
Smolen 2013b
    1. Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque‐Palazuelos F, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918‐29. - PubMed
Smolen 2014b
    1. Smolen JS, Emery P, Fleischmann R, Vollenhoven RF, Pavelka K, Durez P, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 2014;383(9914):321‐32. - PubMed
Smolen 2015
    1. Smolen JS, Emery P, Ferraccioli GF, Samborski W, Berenbaum F, Davies OR, et al. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double‐blind, randomised, placebo‐controlled trial. Annals of the Rheumatic Diseases 2015;74:843‐50. - PMC - PubMed
Sonomoto 2014
    1. Sonomoto K, Yamaoka K, Kubo S, Hirata S, Fukuyo S, Maeshima K, et al. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events. Rheumatology (Oxford) 2014;53(5):914‐8. - PubMed
Soubrier 2009
    1. Soubrier M, Puechal X, Sibilia J, Mariette X, Meyer O, Combe B. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology 2009;49:1429–34. - PubMed
St Clair 2004
    1. Clair EW, Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis and Rheumatism 2004;50(11):3432‐43. - PubMed
Strand 2012
    1. Strand V, Rentz AM, Cifaldi MA, Chen N, Roy S, Revicki D. Health‐related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study. Journal of Rheumatology 2012;39(1):63‐72. - PubMed
Tak 2011
    1. Tak PP, Rigby W, Rubbert‐Roth A, Peterfy C, Vollenhoven RF, Stohl W, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Annals of the Rheumatic Diseases 2011;71(3):351‐7. - PMC - PubMed
Tak 2012
    1. Tak PP, Rigby W, Rubbert‐Roth A, Peterfy C, Vollenhoven RF, Stohl W, et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2‐year results from the randomised controlled trial IMAGE. Annals of the Rheumatic Diseases 2012;71:351–7. - PMC - PubMed
Takeuchi 2014
    1. Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, et al. Adalimumab, a human anti‐TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. Annals of the Rheumatic Diseases 2014;73(3):536‐43. - PMC - PubMed
Tam 2012
    1. Tam L‐S, Shang Q, Li EK, Wang S, Li R‐J, Lee K‐L, et al. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis ‐ a randomized trial. The Journal of Rheumatology 2012;39:2267‐75. - PubMed
Tanaka 2011
    1. Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH, Tofacitinib Study Investigators. Phase II study of tofacitinib (CP‐690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care and Research (Hoboken) 2011;63(8):1150‐8. - PubMed
Tanaka 2012
    1. Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, et al. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO‐FORTH study. Annals of the Rheumatic Diseases 2012;71:817‐24. - PMC - PubMed
Taylor 2004
    1. Taylor PC, Steuer A, Gruber J, Cosgrove DO, Blomley MJ, Marsters PA, et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo‐controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis and Rheumatism 2004;50(4):1107‐16. - PubMed
Taylor 2006
    1. Taylor PC, Steuer A, Gruber J, McClinton C, Cosgrove DO, Blomley MJ, et al. Ultrasonographic and radiographic results from a two‐year controlled trial of immediate or one‐year‐delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. Arthritis and Rheumatism 2006;54(1):47‐53. - PubMed
Van der Heidje 2013
    1. Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve‐month data from a twenty‐four‐month phase III randomized radiographic study. Arthritis and Rheumatism 2013;65(3):559‐70. - PubMed
Van der Kooij 2009
    1. Kooij SM, Cessie S, Goekoop‐Ruiterman YP, Vries‐Bouwstra JK, Zeben D, Kerstens PJ, et al. Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Annals of the Rheumatic Diseases 2009;68(7):1153‐8. - PubMed
Van Vollenhoven 2009
    1. Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Coster L, Waltbrand E, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1‐year results of a randomised trial. Lancet 2009;374(9688):459‐66. - PubMed
Van Vollenhoven 2012a
    1. Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. New England Journal of Medicine 2012;367:508‐19. - PubMed
Van Vollenhoven 2012b
    1. Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, et al. Conventional combination treatment versus biological treatment in methotrexate‐refractory early rheumatoid arthritis: 2 year follow‐up of the randomised, non‐blinded, parallel‐group Swefot trial. Lancet 2012;379:1712‐20. - PubMed
Vital 2015
    1. Vital EM, Dass S, Buch MH, Rawstron AC, Emery P. An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial. Annals of the Rheumatic Diseases 2015;74:1195–201. - PubMed
Weinblatt 1999
    1. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. New England Journal of Medicine 1999;340:253‐9. - PubMed
Weinblatt 2003
    1. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti‐tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis and Rheumatology 2003;48:35‐45. - PubMed
Weinblatt 2006
    1. Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease‐modifying antirheumatic drugs: a one‐year randomized, placebo‐controlled study. Arthritis and Rheumatology 2006;54:2807‐16. - PubMed
Weinblatt 2007
    1. Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Annals of the Rheumatic Diseases 2007;66:228–34. - PMC - PubMed
Weinblatt 2008
    1. Weinblatt ME, Schiff MH, Ruderman EM, Bingham CO 3rd, Li J, Louie J, et al. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double‐blind, active drug‐controlled study. Arthritis and Rheumatism 2008;58(7):1921‐30. - PubMed
Weinblatt 2012
    1. Weinblatt ME, Fleischmann R, Huizinga TW, Emery P, Pope J, Massarotti EM, et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology 2012;51:2204‐14. - PubMed
Weinblatt 2013a
    1. Weinblatt ME, Schiff M, Valente R, Heijde D, Citera G, Zhao C, et al. Head‐to‐head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 2013;65(1):28‐38. - PMC - PubMed
Weinblatt 2013b
    1. Weinblatt ME, Schiff M, Valente R, Heijde D, Citera G, Zhao C, et al. Head‐to‐head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis and Rheumatism 2013;65(1):28‐38. - PMC - PubMed
Weinblatt 2014
    1. Weinblatt ME, Westhovens R, Mendelsohn AM, Kim L, Lo KH, Sheng S, et al. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO‐FURTHER trial. Annals of the Rheumatic Diseases 2014;73(12):2152‐9. - PMC - PubMed
Weisman 2003
    1. Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti‐tumor necrosis factor‐alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clinical Therapeutics 2003;25:1700‐21. - PubMed
Weisman 2007
    1. Weisman MH, Paulus HE, Burch FX, Kivitz AJ, Fierer J, Dunn M, et al. A placebo‐controlled, randomized, double‐blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology 2007;46:1122‐5. - PubMed
Westhovens 2006
    1. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo‐controlled trial. Arthritis and Rheumatology 2006;54:1075‐86. - PubMed
Westhovens 2009
    1. Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Clinical efficacy and safety of abatacept in methotrexate‐naive patients with early rheumatoid arthritis and poor prognostic factors. Annals of the Rheumatic Diseases 2009;68:1870–7. - PMC - PubMed
Westhovens 2014
    1. Westhovens R, Weinblatt ME, Han C, Kim L, Mack M, Lu J, et al. Health‐related quality of life of patients with rheumatoid arthritis achieving DAS28 remission, improvement in physical function and no radiographic progression. Annals of the Rheumatic Diseases 2014;73:479‐80.
Yamamoto 2014b
    1. Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, et al. Efficacy and safety of certolizumab pegol without methotrexate co‐administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo‐controlled trial. Modern Rheumatology 2014;24(4):552‐60. - PubMed
Yamanaka 2014
    1. Yamanaka H, Ishiguro N, Takeuchi T, Miyasaka N, Mukai M, Matsubara T, et al. Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate‐treated Japanese patients with early rheumatoid arthritis: 52‐week results of the HOPEFUL‐1 trial. Rheumatology (Oxford) 2014;53(5):904‐13. - PMC - PubMed
Yazici 2012
    1. Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease‐modifying antirheumatic drugs: the ROSE study. Annals of the Rheumatic Diseases 2012;71:198‐205. - PubMed
Zhang 2006
    1. Zhang F, Hou Y, Huang F, Wu D, Bao C, Ni L, et al. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from China. APLAR Journal of Rheumatology 2006;9:127‐30.

Additional references

Aletaha 2010
    1. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62(9):2569‐81. - PubMed
Alonso‐Ruiz 2008
    1. Alonso‐Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and meta analysis of efficacy and safety. BMC Musculoskeletal Disorders 2008;9:52. - PMC - PubMed
Arnett 1988
    1. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 1988;31(3):315‐24. - PubMed
Barlow 1999
    1. Barlow JH, Cullen LA, Rowe IF. Comparison of knowledge and psychological well‐being between patients with a short disease duration (< or = 1 year) and patients with more established rheumatoid arthritis (> or = 10 years duration). Patient Education and Counseling 1999;38:195‐203. - PubMed
Becker 2011
    1. Becker LA, Oxman AD. Chapter 22: Overviews of Reviews. In: Higgins JP, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Blumenauer 2002
    1. Blumenauer B, Judd M, Wells G, Burls A, Cranney A, Hochberg M, et al. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD003785] - DOI - PMC - PubMed
Boers 2001
    1. Boers M. Treatment of early disease. Rheumatic Diseases Clinics of North America 2001;27:405‐14, x. - PubMed
Bongartz 2006
    1. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti‐TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta‐analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295(19):2275‐85. - PubMed
Bongartz 2009
    1. Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta‐analysis of randomised controlled trials. Annals of the Rheumatic Diseases 2009;68(7):1177‐83. - PubMed
Bradburn 2007
    1. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta‐analytical methods with rare events. Statistics in Medicine 2007;26:53‐77. - PubMed
Brennan 2008
    1. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. Journal of Clinical Investigation 2008;118(11):3537‐45. - PMC - PubMed
Cash 1994
    1. Cash JM, Klippel JH. Second‐line drug therapy for rheumatoid arthritis. New England Journal of Medicine 1994;330(19):1368‐75. - PubMed
Cates 2009 [Computer program]
    1. Dr Chris Cates' EBM web site. Available from www.Nntonline.Net/visualrx/. Visual Rx NNT Calculator version 3. Dr Chris Cates' EBM web site. Available from www.Nntonline.Net/visualrx/, Accessed 13 February 2009.
Choy 2001
    1. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. New England Journal of Medicine 2001;344(12):907‐16. - PubMed
Chung 2006
    1. Chung CP, Thompson JL, Koch GG, Amara I, Strand V, Pincus T. Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta‐analysis of discriminant capacities. Annals of the Rheumatic Diseases 2006;65(12):1602‐7. - PMC - PubMed
Connell 2006
    1. Connell L, McInnes IB. New cytokine targets in inflammatory rheumatic diseases. Best Practice and Research Clinical Rheumatology 2006;20(5):865‐78. - PubMed
Cope 2008
    1. Cope AP. T cells in rheumatoid arthritis. Arthritis Research and Therapy 2008;10 Suppl 1:S1. - PMC - PubMed
Deeks 2011
    1. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
DerSimonian 2007
    1. DerSimonian R, Kacker R. Random‐effects model for meta‐analysis of clinical trials: an update. Contemporary Clinical Trials 2007;28(2):105‐14. - PubMed
Desai 2012
    1. Desai RJ, Hansen RA, Rao JK, Wilkins TM, Harden EA, Yuen A, et al. Mixed treatment comparison of the treatment discontinuations of biologic disease‐modifying antirheumatic drugs in adults with rheumatoid arthritis. Ann Pharmacother 2012;46(11):1491‐505. - PubMed
Dias 2011
    1. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials. 1–39 (2011). Available at www.nicedsu.org.uk. - PubMed
Donahue 2008
    1. Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, et al. Systematic review: comparative effectiveness and harms of disease‐modifying medications for rheumatoid arthritis. Annals of Internal Medicine 2008;148(2):124‐34. - PubMed
Drugs 2006
    1. Drug Information Online. Drugs.com. FDA Approves First Rheumatoid Arthritis Indication for Rituxan. www.drugs.com/news/fda‐approves‐first‐rheumatoid‐arthritis‐indication‐ri... 03/01/2006.
EMA 2001
    1. European Medicines Agency (EMA). EMA Public Statement on Infliximab (Remicade): Increased incidence of mortality and hospitalization for worsening Congestive Heart Failure. www.emea.europa.eu/pdfs/human/press/pus/325701en.pdf.
EMA 2003
    1. European Medicines Agency (EMA). EMA public statement: Increased risk of serious infection and neutropenia in patients treated concurrently with Kineret (anakinra) and Enbrel (etanercept). www.emea.europa.eu/humandocs/PDFs/EPAR/kineret/3163102en.pdf.
EMA 2004
    1. European Medicines Agency (EMA). EPARs for authorized medicinal products for human use: Anakinra: European Public Assessment Report. www.emea.europa.eu/humandocs/Humans/EPAR/kineret/kineret.htm Revision 11, published 27/01/09.
EMA 2009a
    1. European Medicines Agency (EMA). Remicade (inflixmab). www.emea.europa.eu/humandocs/PDFs/EPAR/Remicade/H‐240‐PI‐en.pdf.
EMA 2009b
    1. European Medicines Agency (EMA). EPARs for authorized medicinal products for human use: Humira: European Public Assessment Report. www.emea.europa.eu/humandocs/Humans/EPAR/humira/humira.htm Revision 15, Published 11/05/09.
FDA 2004
    1. Food, Drug Administration. Safety information. October 2004. www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforH....
FDA 1998
    1. Food, Drug Administration. Etanercept Product Approval Information‐ Licensing Action 12/2/1998. www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandAppr... 1998.
FDA 1999
    1. Food, Drug Administration. Remicade® (infliximab) for IV Injection. www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelo... 1999.
FDA 2001
    1. Food, Drug Administration. Kineret® (anakinra) Physician packet insert: Kineret® (anakinra) prescribing information. www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandAppr... 2001.
FDA 2002
    1. Food, Drug Administration. Package Insert. HUMIRA® (adalimumab). Abbott Laboratories. www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandAppr... 2002.
FDA 2005
    1. Food, Drug Administration. Patient Information Sheet. Abatacept (marketed as Orencia®). www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandAppr... 2005.
FDA 2006
    1. Food, Drug Administration. Rituxan® (rituximab). www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedica....
FDA 2007
    1. Food, Drug Administration. Drug details: Orencia. www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Sear....
FDA 2008a
    1. Food, Drug Administration. Humira (adalimumab): Highlights of prescribing information. www.accessdata.fda.gov/drugsatfda_docs/label/2008/125057s114lbl.pdf.
FDA 2008b
    1. Food, Drug Administration. FDA: Manufacturers of TNF‐blocker drugs must highlight risk of fungal infections. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116942.htm.
FDA 2008c
    1. Food, Drug Administration. Medication Guide: Enbrel® (etanercept). www.accessdata.fda.gov/drugsatfda_docs/label/2008/103795s5359lbl.pdf.
FDA 2008d
    1. Food, Drug Administration. CDER New Molecular Entity (NME) Drug and New Biologic Approvals for Calendar Year 2008. CDER report. Application number:125160. www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelo... December 31, 2008.
FDA 2009
    1. Food, Drug Administration. Remicade® (infliximab) for IV Injection. www.accessdata.fda.gov/drugsatfda_docs/label/2009/103772s5234lbl.pdf.
FDA 2009a
    1. Food, Drug Administration. Safety information. Rituxan (Ritiximab). www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforH... 2009.
FDA 2010
    1. Food, Drug Administration. CDER report. Application number: L 125276/0.0, December 31, 2010. CDER New Molecular Entity (NME) & New BLA Calendar Year Approvals. As of December 31, 2010. www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelo... 2010.
FDA 2012
    1. Food, Drug Administration. CDER New Molecular Entity (NME) & New BLA Calendar Year Approvals As of December 31, 2012. www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelo... 2012.
FDA 2015
    1. Food, Drug Administration. Risk Evaluation and Mitigation Strategy (REMS). NDA 203,214 XELJANZ® (TOFACITINIB). www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationfo....
Felson 1995
    1. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis and Rheumatism 1995;38(6):727‐35. - PubMed
Finckh 2006
    1. Finckh A, Liang MH, Herckenrode CM, Pablo P. Long‐term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta‐analysis. Arthritis and Rheumatism 2006;55(6):86‐72. - PubMed
Fransen 2005
    1. Fransen J, Riel PL. The Disease Activity Score and the EULAR response criteria. Clinical and Experimental Rheumatology 2005;23(5 Suppl 39):S93‐9. - PubMed
Fries 1980
    1. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis and Rheumatism 1980;23(2):137‐45. - PubMed
Furst 2008
    1. Furst DE, Keystone EC, Kirkham B, Fleischmann R, Mease P, Breedveld FC, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Annals of the Rheumatic Diseases 2008;67 Suppl 3(Suppl 3):iii2‐25. - PubMed
Furst 2010
    1. Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases 2009. Annals of the rheumatic diseases 2010;69:Suppl 1:i2‐29. - PubMed
Furst 2012
    1. Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, Benedetti F, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases 2011. Annals of the rheumatic diseases 2012;71(Suppl 2):i2‐45. - PubMed
Gabay 2013a
    1. Gabay C, Emery P, Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double‐blind, controlled phase 4 trial. Lancet 2013;381(9877):1541‐50. - PubMed
Gartlehner 2006
    1. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. The Journal of Rheumatology 2006;33(12):2398‐408. - PubMed
Ghogomu 2014
    1. Ghogomu EA, Maxwell LJ, Buchbinder R, Rader T, Pardo Pardo J, Johnston RV, et al. Updated method guidelines for Cochrane Musculoskeletal Group systematic reviews and meta‐analyses. The Journal of Rheumatology 2014;41(2):194‐205. - PubMed
Ghoreschi 2009
    1. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009;228(1):273‐87. - PMC - PubMed
Guyatt 2008
    1. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck‐Ytter Y, Schünemann HJ. What is "quality of evidence" and why is it important to clinicians?. BMJ May 3, 2008;336(7651):995‐8. - PMC - PubMed
Health Canada 2006
    1. Health Canada. Important Safety Information on anti‐TNFα Therapy: Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab) ‐ for health professionals. www.hc‐sc.gc.ca/dhp‐mps/medeff/advisories‐avis/prof/_2006/anti‐tnf_therap_hpc‐c....
Health Canada 2006b
    1. Health Canada. Possible association of Remicade (infliximab) with hepatosplenic T‐cell lymphoma in pediatric and young adult patients with Crohn's disease ‐ for health professionals. www.hc‐sc.gc.ca/dhp‐mps/medeff/advisories‐avis/prof/_2006/remicade_3_hpc‐cps‐en....
Health Canada 2009
    1. Health Canada. Association of Enbrel (etanercept) with histoplasmosis and other invasive fungal infections ‐ for health professionals. www.hc‐sc.gc.ca/dhp‐mps/medeff/advisories‐avis/prof/_2009/enbrel_hpc‐cps‐eng.php.
Higgins 2002
    1. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21:1539‐58. - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Ioannidis 2004
    1. Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004;141(10):781‐8. - PubMed
Kristensen 2011
    1. Kristensen LE, Jakobsen AK, Bartels EM, Geborek P, Bliddal H, Saxne T, et al. The number needed to treat for second‐generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials. Scandinavian Journal of Rheumatology 2011;40(1):1‐7. - PubMed
Kristensen 2007
    1. Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold‐Samsoe B, Saxne T. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. Scandinavian Journal of Rheumatology 2007;36:411‐7. - PubMed
Kvien 2004
    1. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004;22(2 Suppl 1):1‐12. - PubMed
Kvien 2005
    1. Kvien TK, Uhlig T. Quality of life in rheumatoid arthritis. Scandinavian Journal of Rheumatology 2005;34(5):333‐41. - PubMed
Larsen 1977
    1. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiologica: Diagnosis (Stockholm) 1977;4:481‐91. - PubMed
Lee 2001
    1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358(9285):903‐11. - PubMed
Lee 2008
    1. Lee YH, Woo JH, Rho YH, Choi SJ, Ji JD, Song GG. Meta‐analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. Rheumatology International 2008;28(6):553‐9. - PubMed
Leombruno 2008
    1. Leombruno JP, Einarson TR, Keystone EC. The safety of anti‐tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure‐adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68(7):1136‐45. - PubMed
Lethaby 2013
    1. Lethaby A, Lopez‐Olivo MA, Maxwell L, Burls A, Tugwell P, Wells GA. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 2013, Issue 5. [DOI: 10.1002/14651858.CD004525.pub2] - DOI - PMC - PubMed
Liberati 2009
    1. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009;6:e1000100. - PMC - PubMed
Lopez‐Olivo 2012
    1. Lopez‐Olivo MA, Tayar JH, Martinez‐Lopez JA, Pollono EN, Cueto JP, Gonzales‐Crespo MR, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta‐analysis. JAMA 2012;308(9):898‐908. - PubMed
Lopez‐Olivo 2013
    1. Lopez‐Olivo A, Bavineni M, Suarez‐Almazor ME. Tofacitinib for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD010476] - DOI
Lopez‐Olivo 2015
    1. Lopez‐Olivo MA, Amezaga Urruela M, McGahan L, Pollono EN, Suarez‐Almazor ME. Rituximab for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2015, Issue 1. [DOI: 10.1002/14651858.CD007356.pub2] - DOI - PMC - PubMed
Lubeck 2004
    1. Lubeck DP. Patient‐reported outcomes and their role in the assessment of rheumatoid arthritis. Pharmacoeconomics 2004;22(2 Suppl 1):27‐38. - PubMed
Maxwell 2009
    1. Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007277.pub2] - DOI - PMC - PubMed
Mertens 2009
    1. Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD005121.pub3] - DOI - PubMed
Mustafa 2013
    1. Mustafa RA, Santesso N, Brozek J, Akl EA, Walter SD, Norman G, et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. Journal of Clinical Epidemiology 2013;66(7):736‐42. - PubMed
Nam 2010
    1. Nam JL, Winthrop KL, Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, et al. Current evidence for the management of rheumatoid arthritis with biological disease‐modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010;69(6):976‐86. - PubMed
Navarro‐Sarabia 2005
    1. Navarro‐Sarabia F, Ariza‐Ariza R, Hernandez‐Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD005113.pub2] - DOI - PubMed
Nixon 2007
    1. Nixon RM, Bansback N, Brennan A. Using mixed treatment comparisons and meta‐regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Statistics in Medicine 2007;26(6):1237‐54. - PubMed
Odegard 2005
    1. Odegard S, Finset A, Kvien TK, Mowinckel P, Uhlig T. Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7‐year study from the Oslo RA register. Scandinavian Journal of Rheumatology 2005;34(6):441‐7. - PubMed
Orme 2012
    1. Orme ME, Macgilchrist KS, Mitchell S, Spurden D, Bird A. Systematic review and network meta‐analysis of combination and monotherapy treatments in disease‐modifying antirheumatic drug‐experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70. Biologics : targets & therapy 2012;6:429‐64. - PMC - PubMed
Osiri 2003
    1. Osiri M, Suarez‐Almazor ME, Wells GA, Robinson V, Tugwell P. Number needed to treat (NNT): implication in rheumatology clinical practice. Annals of the Rheumatic Diseases 2003;62:316‐21. - PMC - PubMed
O’Sullivan 2007
    1. O'Sullivan LA, Liongue C, Lewis RS, Stephenson SE, Ward AC. Cytokine receptor signaling through the Jak‐Stat‐Socs pathway in disease. Mol Immunol 2007;44(10):2497‐506. - PubMed
Pincus 1983
    1. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis and Rheumatism 1983;26(11):1346‐53. - PubMed
Pincus 2002
    1. Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Kushner I, et al. Evidence from clinical trials and long‐term observational studies that disease‐modifying anti‐rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology (Oxford) 2002;41(12):1346‐56. - PubMed
Prevoo 1996
    1. Prevoo ML, Gestel AM, T Hoff MA, Rijswijk MH, Putte LB, Riel PL. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. British Journal of Rheumatology 1996;35(11):1101‐5. - PubMed
Puhan 2014
    1. Puhan MA, Schunemann HJ, Murad MH, Li T, Brignardello‐Petersen R, Singh JA, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta‐analysis. BMJ 2014;349:g5630. - PubMed
Revman 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Ruiz Garcia 2014
    1. Ruiz Garcia V, Jobanputra P, Burls A, Cabello JB, Vela Casasempere P, Bort‐Marti S, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database of Systematic Reviews 2014, Issue 9. [DOI: 10.1002/14651858.CD007649.pub3] - DOI - PubMed
Saag 2008
    1. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59(6):762‐84. - PubMed
Salanti 2008
    1. Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Statistical Methods in Medical Research 2008;17(3):279‐301. - PubMed
Schiff 2008
    1. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi‐centre, randomised, double‐blind, placebo‐controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Annals of the Rheumatic Diseases 2008;8:1096‐103. - PMC - PubMed
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Scott 2006
    1. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. New England Journal of Medicine 2006;355(7):704‐12. - PubMed
Sharp 1971
    1. Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis and Rheumatism 1971;14(6):706‐20. - PubMed
Shea 2007
    1. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology 2007;7:10. - PMC - PubMed
Singh 2010a
    1. Singh JA, Beg S, Lopez‐Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2010, Issue 7. [DOI: 10.1002/14651858.CD008331.pub2] - DOI - PubMed
Singh 2010b
    1. Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD008341] - DOI - PMC - PubMed
Singh 2012
    1. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64(5):625‐39. - PMC - PubMed
Singh 2016
    1. Singh JA, Hossain A, Tanjong Ghogomu E, Kotb A, Christensen R, Mudano AS, et al. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease‐modifying anti‐rheumatic drugs: a systematic review and network meta‐analysis. Cochrane Database of Systematic Reviews 2016, Issue 5. [DOI: 10.1002/14651858.CD012183] - DOI - PMC - PubMed
Singh 2016a
    1. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis and Rheumatology 2016;Epub(68):1‐26. [DOI: 10.1002/acr.22783] - DOI - PubMed
Smolen 2014a
    1. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease‐modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73(3):492‐509. - PMC - PubMed
Song 2003
    1. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta‐analyses. BMJ 2003;326:472. - PMC - PubMed
Spiegelhalter 2003
    1. Spiegelhalter D, Thomas A, Best N. WinBUGS user manual. Version 1.4, January 2003.. MRC Biostat. Unit 2. faculty.washington.edu/jmiyamot/p548/spiegelhalter%20winbugs%20user%20ma.... 2003.
Strand 2008
    1. Strand V, Singh JA. Improved health‐related quality of life with effective disease‐modifying antirheumatic drugs: evidence from randomized controlled trials. American Journal of Managed Care 2008;14(4)(4):234‐54. - PubMed
Sweeting 2004
    1. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data. Statistics in Medicine 2004;23:1351‐75. - PubMed
Szekanecz 2007
    1. Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. Current Opinion in Rheumatology 2007;19(3):289‐95. - PubMed
Thompson 1999
    1. Thompson SG, Sharp SJ. Explaining heterogeneity in meta‐analysis: a comparison of methods. Statistics in Medicine 1999;18(20):2693‐708. - PubMed
Thompson 2011
    1. Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta‐analysis of randomized controlled trials. Arthritis Rheum 2011;63(6):1479‐85. - PubMed
Tugwell 2000
    1. Tugwell P, Shea B, Boers M, Brooks P, Simon L, Strand V, et al. “Stepping‐up” from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis. N Engl J Med 2000;343(21):1520–8.
Turner 2012
    1. Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta‐analysis, using empirical data from the Cochrane Database of Systematic Reviews. International Journal of Epidemiology 2012;41(3):818‐27. - PMC - PubMed
Van der Heijde 1989
    1. Heijde DM, Riel PL, Nuver‐Zwart IH, Gribnau FW, Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1(8646):1036‐8. - PubMed
Wells 1993
    1. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. The Journal of Rheumatology 1993;20(3):557‐60. - PubMed
Woolley 2003
    1. Woolley DE. The mast cell in inflammatory arthritis. New England Journal of Medicine 2003;348(17):1709‐11. - PubMed
Yelin 2007
    1. Yelin E. Work disability in rheumatic diseases. Current Opinion in Rheumatology 2007;19(2):91‐6. - PubMed
Zhang 2016
    1. Zhang J, Xie F, Yun H, Chen L, Muntner P, et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis 2016;75(10):1813‐18. - PubMed

MeSH terms

LinkOut - more resources